Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.73 |
| ▸ | MGMT | P16455 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22193718 | 0.93 | SLC29A1 (0.63) | SLC29A1ADORA2AADORA2BMGMTADORA3 | |
| SCHEMBL8971138 | 0.92 | SLC29A1 (0.62) | SLC29A1ADORA2AADORA2BMGMTADORA3 | |
| SCHEMBL8971129 | 0.92 | SLC29A1 (0.62) | SLC29A1ADORA2AADORA2BMGMTADORA3 | |
| SCHEMBL20633954 | 0.89 | SLC29A1 (0.59) | SLC29A1ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL7764449 | 0.86 | HINT1 (0.61) | SLC29A1ADORA2AADORA2BMGMTADORA3 | |
| SCHEMBL5353431 | 0.85 | ADORA3 (0.67) | SLC29A1ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL7054035 | 0.85 | SLC29A1 (1.00) | SLC29A1ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL7054042 | 0.85 | SLC29A1 (1.00) | SLC29A1ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL2218888 | 0.85 | ADORA2A (0.70) | SLC29A1ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5492996 | 0.84 | ADORA2A (1.00) | ADORA2AADORA2BADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545911-B2 | Single-stranded RNA-editing oligonucleotides | PROQR THERAPEUTICS II B.V. (NL) | 2026-02-10 | — | — | US | claimed |
| US-20250223593-A1 | CHEMICALLY MODIFIED SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | PROQR THERAPEUTICS II B.V. (NL) | 2025-07-10 | — | — | US | claimed |
| US-20240417721-A1 | SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | PROQR THERAPEUTICS II B.V. (NL) | 2024-12-19 | — | — | US | claimed |
| US-12018257-B2 | Single-stranded RNA-editing oligonucleotides | PROQR THERAPEUTICS II B.V. (NL) | 2024-06-25 | — | — | US | claimed |
| US-11851656-B2 | Chemically modified single-stranded RNA-editing oligonucleotides | PROQR THERAPEUTICS II B.V. (NL) | 2023-12-26 | — | — | US | claimed |
| US-20230279392-A1 | SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | PROQR THERAPEUTICS II B.V. (NL) | 2023-09-07 | — | — | US | claimed |
| CN-110352244-B | Chemically modified RNA editing single stranded oligonucleotides | ProQR治疗上市公司Ⅱ | 2023-03-21 | — | — | CN | claimed |
| US-10941402-B2 | Chemically modified single-stranded RNA-editing oligonucleotides | PROQR THERAPEUTICS II B.V. (NL) | 2021-03-09 | — | — | US | claimed |
| EP-4689107-A1 | CHEMICALLY MODIFIED ANTISENSE OLIGONUCLEOTIDES FOR USE IN RNA EDITING | ProQR Therapeutics II B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688143-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF LIVER DISEASE | ProQR Therapeutics II B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| EP-4689110-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ProQR Therapeutics II B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| EP-4652275-A1 | DELIVERY OF OLIGONUCLEOTIDES | ProQR Therapeutics II B.V. (NL) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025224230-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF FATTY LIVER DISEASE | PROQR THERAPEUTICS II B.V. (NL) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025215130-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF POLY-Q DISEASE | PROQR THERAPEUTICS II B.V. (NL) | 2025-10-16 | — | — | WO | disclosed |
| CN-1679946-A | Anticarcinogen composition | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | disclosed |
| CN-1679951-A | Medicinal composition for tumor body | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | disclosed |
| CN-1679936-A | Anticarcinogen composition | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | disclosed |
| CN-1679945-A | Anticarcinogen composition | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | disclosed |
| CN-1679944-A | Anticarcinogen composition | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-10-12 | — | — | CN | disclosed |
| CN-1628852-A | Anti solid tumor medicine composition | KONG QINGZHONG (CN) | 2005-06-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545911-B2 | Single-stranded RNA-editing oligonucleotides | ADAR, IDUA, ADA | SLC29A1 211/4885ADORA2A 235/4885ADORA2B 455/4885 |
| US-12018257-B2 | Single-stranded RNA-editing oligonucleotides | ADAR, NSUN3, DCLRE1B | SLC29A1 402/4885ADORA2A 159/4885ADORA2B 454/4885 |
| US-20230279392-A1 | SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | ADAR, NSUN3, DCLRE1B | SLC29A1 400/4885ADORA2A 158/4885ADORA2B 455/4885 |
| US-20240417721-A1 | SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | ADAR, NSUN3, RNGTT | SLC29A1 421/4885ADORA2A 253/4885ADORA2B 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.